| Theme | Testify the concepts of renal osteodystrophy and chronic kidney disease-bone and mineral disorder (CKD-MBD) | |
|---|---|---|
| Title | Role of cinacalcet into resistant cases and expectations for next-generation of calcium-sensing receptor modulators | |
| Publish Date | 2015/06 | |
| Author | Hideki Tahara | Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine |
| [ Summary ] | Cinacalcet has came to be recognized as a drug which is indispensable for CKD-MBD treatment, along with active vitamin D preparations and phosphate binders. Although side effects such as a digestive tract symptoms and hypocalcemia has been observed, it is understood that side effects may be held in check well by treatment regimens. However, cases thought to be refractory to cinacalcet have been observed. The particularly refractory properties of cinacalcet, are the subject of a great deal of vital research. It is hoped that next-generation drugs will produce greater positive effects with decreased adverse side effects. These drugs are currently under development in Japan. | |